Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Works matching AU Chu, Q S C
Results: 2
1
2
Key determinants of energy expenditure in cancer and implications for clinical practice.
- Published in:
- 2016
- By:
- Publication type:
- journal article